Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Serono MS drug shows efficacy in phase III study

Merck Serono MS drug shows efficacy in phase III study

27th October 2010

Merck Serono's new multiple sclerosis (MS) treatment Rebif can help to delay the onset of the condition, according to new study data.

The company has completed a phase III clinical trial called Reflex, which evaluated the interferon beta-1a treatment in its serum-free formulation among 517 patients over two years.

It was found that use of Rebif can help to significantly delay conversion to full MS diagnosis among those who have experienced a clinical event suggestive of the disease, according to analysis by means of the McDonald criteria.

Dr Roberto Gradnik, executive vice-president for neurodegenerative diseases at Merck Serono, said this comes as part of the company's ongoing efforts to enhance its Rebif product offering.

He added: "We are committed to provide treatments that meet the individual needs of people living with MS at the various stages of the disease."

Earlier this month, the company launched RebiDose, a Rebif-based single use pre-filled pen that makes it easier for sufferers to self-administer treatment.ADNFCR-8000103-ID-800160168-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.